XBiotech Completes Enrollment in Global Phase I/II Study for its True Human™ Antibody Treatment for Serious Staphylococcus aureus ...
AUSTIN, Texas, Dec. 06, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, today announced that enrollment has been completed in its randomized, placebo-controlled Phase I/II study evaluating dosing, …